Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 162-168

  Mayer, Otto ^a   Seidlerová, Jitka ^a   Bruthans, Jan ^a   Filipovský, Jan ^a   Timoracká, Katarina ^a   Vaněk, Jiří ^a   Černá, Lenka ^c   Wohlfahrt, Peter ^a,b   Cífková, Renata ^a,b   Theuwissen, Elke ^d   Vermeer, Cees ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Coronary heart disease; Dp cMGP; Dp ucMGP; EUROASPIRE; Matrix gla protein; Mortality; Secondary prevention; Stroke

Indexed keywords

DEPHOSPHO UNCARBOXYLATED MATRIX GLA PROTEIN; MATRIX PROTEIN; OSTEOCALCIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN; MATRIX GLA PROTEIN; SCLEROPROTEIN; VITAMIN K GROUP;

AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC STABLE VASCULAR DISEASE; COHORT ANALYSIS; CZECH REPUBLIC; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; VASCULAR DISEASE; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; HEART MUSCLE ISCHEMIA; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; REGRESSION ANALYSIS; TREATMENT OUTCOME;

AGED; BIOMARKERS; CALCIUM-BINDING PROTEINS; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REVASCULARIZATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STROKE; TREATMENT OUTCOME; VASCULAR DISEASES; VITAMIN K;

EID: 84901829227     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.027     Document Type: Article

References (27)

1. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
2. Greenland P., Bonow R.O., Brundage B.H., Budoff M.J., Eisenberg M.J., Grundy S.M., et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation clinical expert consensus task force (ACCF/AHA writing committee to update the 2000 expert consensus document on electron beam computed Tomography) developed in collaboration with the society of atherosclerosis imaging and prevention and the society of cardiovascular computed tomography. JAm Coll Cardiol 2007, 49:378-402.
3. Pletcher M.J., Tice J.A., Pignone M., Browner W.S. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 2004, 164:1285-1292.
4. Schurgers L.J., Cranenburg E.C.M., Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008, 100:593-603.
5. van den Heuvel E.G., van Schoor N.M., Lips P., Magdeleyns E.J., Deeg D.J., Vermeer C., et al. Circulating uncarboxylated matrix Gla protein, a marker of vitamin K status, as a risk factor of cardiovascular disease. Maturitas 2014, 77:137-141.
6. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008, 3:1504-1510.
7. Shanahan C.M., Proudfoot D., Farzaneh-Far A., Weissberg P.L. The role of Glaproteins in vascular calcification. Crit Rev Eukaryot Gene Expr 1998, 8:357-375.
8. Price P.A., Urist M.R., Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983, 117:765-771.
9. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386:78-81.
10. Cranenburg E.C., Koos R., Schurgers L.J., Magdeleyns E.J., Schoonbrood T.H., Landewé R.B., et al. Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 2010, 104:811-822.
11. Schurgers L.J., Spronk H.M., Skepper J.N., Hackeng T.M., Shanahan C.M., Vermeer C., et al. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. JThromb Haemost 2007, 5:2503-2511.
12. Theuwissen E., Smit E., Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr 2012, 3:166-173.
13. Dalmeijer G.W., van der Schouw Y.T., Vermeer C., Magdeleyns E.J., Schurgers L.J., Beulens J.W. Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. JNutr Biochem 2013, 24:624-628.
14. Ueland T., Gullestad L., Dahl C.P., Aukrust P., Aakhus S., Solberg O.G., et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. JIntern Med 2010, 268:483-492.
15. Ueland T., Dahl C.P., Gullestad L., Aakhus S., Broch K., Skårdal R., et al. Circulating levels of non-phosphorylated undercarboxylated matrix Gla protein are associated with disease severity in patients with chronic heart failure. Clin Sci 2011, 121:119-127.
16. Schlieper G., Westenfeld R., Krüger T., Cranenburg E.C., Magdeleyns E.J., Brandenburg V.M., et al. Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD. JAm Soc Nephrol 2011, 22:387-395.
17. Mayer O., Šimon J., Galovcová M., Hrbková J., Bruthans J., Bělohoubek J., et al. The quality of secondary prevention of coronary heart disease in Czech patients in the EUROASPIRE III survey. Cor Vasa 2008, 50:156-162.
18. Bruthans J., Mayer O., Šimon J., Galovcová M., Hrbková J., Bělohoubek J., et al. The standard of secondary prevention of stroke in Czech patients in the EUROASPIRE III study - stroke specific module. Cor Vasa 2008, 50:446-454.
19. Schurgers L.J., Barreto D.V., Barreto F.C., Liabeuf S., Renard C., Magdeleyns E.J., et al. The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 2010, 5:568-575.
20. Beulens J.W., Bots M.L., Atsma F., Bartelink M.L., Prokop M., Geleijnse J.M., et al. High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis 2009, 203:489-493.
21. Gast G.C., de Roos N.M., Sluijs I., Bots M.L., Beulens J.W., Geleijnse J.M., et al. Ahigh menaquinone intake reduces the incidence of coronary heart disease. Nutr Metab Cardiovasc Dis 2009, 19:504-510.
22. Geleijnse J.M., Vermeer C., Grobbee D.E., Schurgers L.J., Knapen M.H., van der Meer I.M., et al. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. JNutr 2004, 134:3100-3105.
23. 2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant 2013, published online, PMID: 24285428.
24. Dalmeijer G.W., van der Schouw Y.T., Magdeleyns E., Ahmed N., Vermeer C., Beulens J.W., et al. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 2012, 225:397-402.
25. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-1180.
26. Zittermann A., Koerfer R. Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 2008, 29:423-432.
27. Farzaneh-Far A., Weissberg P.L., Proufoot D., C.M. Transcriptional regulation of matrix Gla protein. ZKardiol 2011, 90:38-42.